March 7: “The (R)evolution in the Management of Urothelial Carcinoma”

Oncology clinicians and Asante employees are invited to attend Oncology Grand Rounds. Our guest speaker is Petros Grivas, MD, PhD, who will present on “The (r)evolution in the management of urothelial carcinoma.”
This hour-long CME event takes place at:
Noon – 1 p.m. on Thursday, March 7
Mary and Dick Heimann Cancer Center
3011 E. Barnett Road, Medford
No registration is required, but space is limited.
Dr. Petros Grivas is an oncologist with expertise in treating genitourinary cancers such as bladder cancer, prostate cancer and testicular cancer. His clinical research helped lead to FDA approval of new drugs to treat the most common type of bladder cancer. He currently leads clinical trials that investigate the use of checkpoint inhibitors. These immunotherapy drugs release the brakes on a patient’s immune system and help it mount a better response to cancer.
- Clinical Director, Genitourinary Cancers Program, Fred Hutch Cancer Center
- Professor, Clinical Research Division, Fred Hutch Center
- Professor, Division of Hematology and Oncology, University of Washington School of Medicine